European Pharmaceutical Review Issue 2 2023
EPR Issue 2 includes articles on the future of cell and gene therapy, the potential of AAV gene therapies, NMR relaxometry and more…
List view / Grid view
EPR Issue 2 includes articles on the future of cell and gene therapy, the potential of AAV gene therapies, NMR relaxometry and more…
While there is a keen interest in smart packaging worldwide, adopting these solutions at scale is challenging, a report has asserted.
A paper states ATR-FT-IR spectroscopy plus multivariate analysis for heparin analysis is cost-effective compared to NMR.
A total $3.7 billion investment at LEAP Innovation Park in the US is Eli Lilly and Company’s largest manufacturing investment at a single location in its history.
Between 2023 to 2033, automation in the biopharma industry will be driven by solutions such as robotics and AI, a market report shows.
A paper has reviewed how novel drug delivery systems could achieve stable formulations of nucleic acid therapeutics.
Discover what is driving the oligonucleotide therapeutics sector as scientists navigate challenges such as financing and success-to-market.
Researchers have developed a new automated buffer management system that offers supply to continuous downstream process for 10 days with consistent quality.
From development to distribution, leading global event Interphex 2023 (April 25-27 New York, US) takes you through all stages of the pharma product lifecycle.
Trends such as sustainability and technological advances like AI are helping to boost the microbial fermentation technology market, a report says.
Rapid identification of well-known bacterial species makes MALDI-TOF mass spectrometry a suitable alternative to conventional systems, researchers have stated.
Improvements in real-time supply chain operations is expected to drive the cell and gene therapy supply chain/logistics market, a report says.
Improvements to the pour plate method during rapid microbial assessment could facilitate automation of the technique, according to research.
A novel high resolution mass spectrometer can accurately identify one of most common nosocomial fungal pathogens, researchers have found.
Four UK life sciences companies are set to benefit from a £277m investment in the first tranche of Life Sciences Innovative Manufacturing Fund (LSIMF) grants.